OTCMKTS:NEVPF Abliva AB (publ) (NEVPF) Stock Price, News & Analysis $0.03 0.00 (0.00%) As of 05/2/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About Abliva AB (publ) Stock (OTCMKTS:NEVPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abliva AB (publ) alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.01▼$0.04VolumeN/AAverage Volume4,445 shsMarket Capitalization$11.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Read More… Receive NEVPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address NEVPF Stock News HeadlinesPharming announces public cash offer to shareholders of Abliva ABDecember 16, 2024 | markets.businessinsider.comStillfront Group publ AB (SFRG)July 27, 2024 | investing.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 3, 2025 | Timothy Sykes (Ad)Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial DiseaseJuly 19, 2024 | markets.businessinsider.comAbliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024May 13, 2024 | finance.yahoo.comProbi ABMarch 20, 2024 | barrons.comIVSXF Investor AB (publ)January 10, 2024 | seekingalpha.comInterfox Resources publ AB (IFOX)October 3, 2023 | investing.comSee More Headlines NEVPF Stock Analysis - Frequently Asked Questions How have NEVPF shares performed this year? Abliva AB (publ)'s stock was trading at $0.0360 at the start of the year. Since then, NEVPF stock has decreased by 22.2% and is now trading at $0.0280. View the best growth stocks for 2025 here. How do I buy shares of Abliva AB (publ)? Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:NEVPF CIKN/A Webwww.neurovive.com Phone(646) 275-6220Fax46-4-688-883-48Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-117.92% Return on Assets-102.44% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,128.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book1.40Miscellaneous Outstanding Shares403,010,000Free FloatN/AMarket Cap$11.28 million OptionableNot Optionable Beta-1.18 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:NEVPF) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abliva AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Abliva AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.